Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission
|
|
- Stephen Cameron
- 1 years ago
- Views:
Transcription
1 April 2014 Committee for Medicinal Products for Human Use (CHMP) Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission Draft Draft Agreed by Biologics Working Party April 2014 Adoption by CHMP for release for consultation 25 April 2014 Start of public consultation 1 May 2014 End of consultation (deadline for comments) 31 October Comments should be provided using this template. The completed comments form should be sent to 9 10 Keywords active substance, biologics, process validation, process evaluation, process verification, lifecycle 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0) Facsimile +44 (0) Website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission Table of contents Table of contents... 2 Executive summary Introduction Scope Legal basis Process development Process validation Process evaluation Process verification Ongoing process verification Points to consider in process validation Upstream process Downstream process Multifacility production... 9 Definitions References /11
3 Executive summary The guideline covers process validation of biotechnology-derived proteins used as active substance in the manufacture of medicinal products. This guideline addresses the data requirements for process validation for submission of a marketing authorisation application or variation. Process Validation can be based on a traditional or enhanced approach to process development. Traditional and enhanced approaches are not mutually exclusive. A company can use either a traditional approach or an enhanced approach to process validation, or a combination of both. Regardless of the approach followed, the validation data to be included in the regulatory submission should cover information relating to the evaluation and the verification of the manufacturing process. 1. Introduction Process validation is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an active substance or intermediate meeting its predetermined specifications and quality attributes (ICH Q7). Process validation studies should normally be completed and included in the marketing authorisation application or a variation application if relevant. It is acknowledged that process validation activities do not end at the time of the marketing authorisation, but continue through the lifecycle of the product and its process. This document addresses the information expected to be presented in a regulatory submission to demonstrate that the manufacturing process described in the Common Technical Document (CTD) section S.2.2 Description of manufacturing process and process controls consistently performs as intended. This information normally includes process evaluation and verification studies. Process evaluation studies, performed at small and/or full scale, should provide evidence that the complete manufacturing process and each step/operating unit have been appropriately designed and are controlled to obtain a product of the intended quality. Process verification studies should confirm that the final manufacturing process performs effectively and is able to produce an active substance or intermediate meeting its predetermined acceptance criteria, on an appropriate number of consecutive batches produced with the commercial process and scale. Subsequent to successful process validation activities for regulatory submission, product quality and process performance must be maintained in a state of control throughout the commercial part of the product lifecycle. These activities have to be performed in compliance with EU Good Manufacturing Practices (GMP). 2. Scope This document provides guidance on the data to be included in a regulatory submission to demonstrate that the active substance manufacturing process is in a validated state. The principles adopted and explained in this document apply to recombinant proteins and polypeptides, their derivatives, and products of which they are components (e.g. conjugates), as defined in ICH Q6B. The principles that are outlined in the document may also apply to other biological products such as vaccines or blood products, as appropriate. To determine applicability, manufacturers should consult with the appropriate regulatory authorities. For evaluation of viral safety, please refer to ICH Q5A. 3/11
4 Legal basis This guideline has to be read in conjunction with the introduction and general principles (4) and Part II of Annex I to Directive 2001/83/EC as amended. 4. Process development The goal of manufacturing process development for the active substance is to establish a commercial manufacturing process capable of consistently producing an active substance of the intended quality. Although not considered as part of process validation, process development comprises an essential role in defining the criteria and conditions to be addressed in process validation studies. For further information, please refer to ICH Q11 guideline. Manufacturing process development should identify which inputs (e.g. material attributes, process parameters) and outputs (e.g. quality attributes, process indicators) for each process step/unit operation should be further evaluated during process validation studies. Documented prior knowledge and risk assessment can help identify and justify the material attributes (e.g. of raw materials, starting materials, reagents, solvents, process aids, intermediates) and process parameters with the potential for having an effect on active substance critical quality attributes (CQAs) and/or process performance. Process development information should usually be submitted in Section 3.2.S.2.6 of the CTD. 5. Process validation A prospective process validation, as defined in ICH Q7, is expected for biotechnology-derived active substances. Process validation activities would normally include i) evaluation that process steps and the complete process are capable to perform as intended and ii) verification on commercial scale batches that the process does perform as intended. The contribution of data from small scale studies to the overall validation package will depend upon demonstration that the small scale model is an appropriate representation of the proposed commercial scale. Successful demonstration of the suitability of the small scale model could reduce data requirements for process verification (e.g. reduced number of batches) and/or impact on control strategy (e.g. alternative approach to end product testing, ongoing process verification) by evaluation and understanding of the sources of variability of CQAs. This is further discussed below. The set of controls used in process validation activities (e.g. quality attribute, process indicator, process parameter, controls implicit in the design of the process) are expected to go beyond the routine control system as described in S.2.2 and S.2.4. Considering that evaluation and verification activities are often investigated in the same study, it is not always necessary to make a difference between these activities as long as the evidences required for their demonstration are appropriately presented. Process validation information should usually be submitted in Section 3.2.S.2.5 of the CTD Process evaluation Process evaluation studies should provide evidence that, when operating in accordance with the Description of manufacturing process and process controls (CTD section S.2.2), the complete manufacturing process and each step/operating unit have been appropriately designed and controlled 4/11
5 to obtain a product of the intended quality. Successful process evaluation should thus demonstrate that the design of the manufacturing process and its control are appropriate for commercial manufacturing. The applicant should base the inputs and outputs studied on their potential criticality and justify their selection. For those which are not studied further it may be needed to explain how it is ascertained that these are kept within the range that has been shown to be non-critical. These studies should include the evaluation of the ability of each step to obtain a product or intermediate of desired quality at small and/or full scale as appropriate, when operating in accordance with the described process and process controls. The results of inputs and outputs should be presented for each step. These data should demonstrate that when operating within the proposed input ranges, the output meets relevant quality criteria (i.e. predefined acceptance criteria or internal limits), and thus support the proven acceptable ranges (PAR). The outcome of the evaluation studies serves as the main basis of defining the control strategy and also in setting the acceptance criteria for the verification studies. Where appropriate, evaluation of selected step(s) operating in worst case and/or abnormal conditions (e.g. cumulative hold time, spiking challenge) could be performed to support or demonstrate the robustness and the capability of the process to deliver product of the intended quality in these conditions. In some cases, these activities could be built into process verification studies (e.g. lots produced with intermediates stored in worst case hold conditions). Small scale models are important tools in the development and evaluation of biopharmaceutical manufacturing processes. During process evaluation, small scale models enable evaluation of input material and parameter variability to an extent that may not be feasible at manufacturing scale. A small scale model must be designed and executed, and ultimately demonstrated, as an appropriate representation of the manufacturing process. It is acknowledged that small scale models are incomplete representations of commercial scale process. When used, small scale models should be described and their relevance for the commercial scale should be justified, in terms of objective, design, inputs and outputs. When validation studies are highly dependent on the small scale model studies (e.g. design space claimed), it may be necessary to demonstrate that when operating under the same conditions using the same input materials, the outputs resulting from the commercial scale process match those of the small scale model. Any difference in operating conditions, inputs or outputs should be appropriately justified. Depending on the differences observed and their understanding, approaches to manage these differences (e.g. use of correction factors in cases where Design of Experiments is used) could be acceptable if well documented and justified. The use of such an approach requires appropriate management of the risks linked to this uncertainty (e.g. managed through control strategy). Where prior knowledge or platform manufacturing experience is utilised, the contribution of these data (e.g. to justify operating ranges, input set points) to the overall validation package will depend upon justification that the data is representative of the proposed commercial process. Usually, full scale validation studies should include data derived from the final manufacturing process and site(s) used to produce the product to be commercialised Process verification Process verification studies should confirm that the final manufacturing process (i.e. full scale commercial process) performs effectively and is able to produce an active substance or intermediate 5/11
6 meeting its predetermined controls and acceptance criteria. Such studies are generally performed in accordance to the expected normal operating ranges (NORs). Process verification data (including process step results, batch analyses) should normally be completed and presented in the regulatory submission on an appropriate number of consecutive batches produced with the commercial process and scale, taking into account the batch definition as detailed in the process description. Failure to present validation data on consecutive batches should be appropriately justified. The number of batches to be presented depends on several factors including but not limited to: (1) the complexity of the process being validated; (2) the level of process variability; (3) the amount of experimental data and/or process knowledge available on the process; and (4) the frequency and cause(s) of deviations and batch failure. As an alternative approach, continuous process verification could facilitate acceptance of fewer batches in the verification studies. The success of such an approach will be highly dependent on the knowledge and understanding gained on the process and product, and the process analytical technologies deployed to control and monitor the process inputs and outputs in an uninterrupted manner. In the case that a design space is claimed, it may be needed to include a protocol on how movement within the design space will be managed post approval to verify that the design space is still valid when run at commercial scale. Please refer to ICH Q11 for further details Ongoing process verification Subsequent to successful process validation activities for regulatory submission, companies should monitor product quality and process performance to ensure that a state of control is maintained throughout the commercial part of the product lifecycle. These activities have to be performed in compliance with EU GMP, and should provide evidence of the continued capability of the process and controls to produce product that meets the desired quality through the lifecycle of the product. 6. Points to consider in process validation 6.1. Upstream process Process validation of the upstream process normally includes evaluation and verification that the cell culture steps, from the introduction of the starting material in the manufacturing process (e.g. thaw of the working cell bank (WCB)) up to the collection of the last harvest obtained at/or beyond production level are capable to perform as intended. Considering the complex matrices during cell culture and harvest steps, the evaluation/validation could, in part, rely on the analysis of active substance and/or intermediates obtained at a later stage of the process Evaluation of upstream process Process evaluation activities should demonstrate that the cell culture steps, from the introduction of the starting material in the manufacturing process (e.g. thaw of the WCB) up to and/or beyond production level, are capable of consistently delivering inoculates, harvest(s), and ultimately an active substance of appropriate quality. Several aspects should be considered when validating cell culture. The level of detail provided should support the criticality assignment of process parameters. These activities could include evaluation of specific cell traits or indices (e.g. morphological characteristics, growth characteristics (population doubling level), cell number, viability, biochemical 6/11
7 markers, immunological markers, productivity of the desired product, oxygen or glucose consumption rates, ammonia or lactate production rates), process parameters and operating conditions (e.g. time, temperatures, agitation rates, working volumes, media feed, induction of production). The conditions utilised to end fermentation/cell culture cycle and initiate harvest should be appropriately defined and evaluated. Relevant information on the final culture steps (e.g. yield, maximum generation number or population doubling level, consistency of cell growth, viability, duration and microbial purity) should be presented. Potential impact of raw materials (e.g. quality of media, supplements, treatment such as gamma irradiation of animal sera) should be evaluated, in the light of the variability of these materials (e.g. intrinsic to the material, related to change in supplier) and of their influence on the quality of the product. Where appropriate, a risk-based approach could be presented to illustrate how variability of these raw materials and their related risks are managed through the lifecycle of the product (e.g. included in ongoing process verification protocol) Verification of upstream process Process verification activities should focus on the confirmation of consistency of performance indicators and quality attributes when operating conditions and process parameters are in accordance to NORs. These studies should include all culture steps and cover the complete duration of the process, on an appropriate number of consecutive runs General issues related to single use equipment When single use equipment is used, in development studies consideration should be given to leachables and extractables. Information should be provided on the nature and amount of potential leachables, their impact on the cell culture, and the removal of such impurities. Besides data this normally includes a risk assessment. For validation full scale equipment has to be used. Various batches of disposable systems should be used in the manufacturing of verification batches in order to assess their impact on the product quality General issues related to multiple harvests Where multiple harvests from one cell culture run are collected, it should be demonstrated that the increasing cell age during the culture run does not have an impact on quality and intra-batch consistency (i.e. derived from initial harvest through to last harvest) and inter-batch (i.e. derived from different fermentation runs / cell culture cycles). Such evidence could be supported by appropriate analysis of performance indicators (e.g. yield, titre) and quality attributes (e.g. post-translational modifications, host cell proteins (HCP), DNA) which should be confirmed to be consistent throughout the harvesting steps, otherwise an approach to manage the variability of harvests (e.g. by suitable pooling strategy) should be proposed. As certain analyses of quality attributes (e.g. post-translational modifications) may be difficult in a crude matrix, there may be a need for a partial, small scale purification of single harvests representative of early, mid and late stages of the cell culture cycle, to assess the effect of an aging cell population on the integrity of the product and to provide a scientific basis for the establishment of termination criteria. The verification of the consistency of batches based on several fermentations runs/ cell culture cycles could lead to the necessity of producing a large number of batches spanning a long production period. In such situation, an applicant may propose a protocol to verify the consistency of these batches through ongoing process verification. 7/11
8 Downstream process Downstream processing starts with the first step after final harvest and leads to a product of the desired quality: it may include steps required for cell disruption, concentration of drug intermediates and impurity clearance, polishing procedures but also protein refolding or potential modifications for the protein of interest. Most frequently various chromatographic and filtration methods are applied. In certain cases, specific steps aiming at a modification of the intermediate (e.g. conjugation to other proteins, carbohydrates or chemicals, e.g. pegylation) are included Evaluation of downstream process The capacity of the proposed purification procedures to deliver the desired product and to remove product and process-related impurities (e.g. unwanted variants, HCPs, nucleic acids, media components, viruses, reagents used in modification of the protein) to acceptable levels should be thoroughly evaluated. This generally includes establishment of adequate analytical methods required for their detection and an estimation of the concentrating or removing capacity for each unit operation followed by the determination of appropriate acceptance criteria. For certain process-related impurities (e.g. HCP, DNA, antibiotics) scale-down spiking experiments may be required to determine the removal capacity of the individual purification steps. Evaluation of selected purification step(s) (e.g. steps for which high impurity or viral clearance are claimed) operating in worst case and/or abnormal conditions (e.g. cumulated hold times, spiking challenge) could be performed to document the robustness of the process. Process conditions (e.g. column loading capacity, flow rate, length, elution/washing conditions conditions) and performance parameters/indicators (e.g. yield, chromatographic profiles) should be appropriately evaluated. In the case where feed forward and/or feedback loop systems are used to accommodate the conditions of process steps, all claimed conditions should be appropriately evaluated regarding their impact on output material(s), according to an appropriate design of experiments, and verified according to an approved protocol. Columns should also be evaluated throughout the expected lifetime of the column regarding purification ability (e.g. clearance, collection of intended variants), leaching of ligands (e.g. dye, affinity ligand) and/or chromatographic material (e.g. resin). Absence of specific leaching studies may be acceptable for some resins with small molecule functional group, but requires appropriate justification. Considering the number of purification cycles required for this evaluation, small scale studies are considered appropriate to estimate and set the maximum number of cycles at the time of regulatory submission, provided that full scale verification is performed on an ongoing basis, to confirm the column performance and integrity, in accordance with an approved protocol Verification of downstream process Verification activities should confirm the clearance capability of the entire downstream process, showing that process parameters and performance indicators - in accordance to normal acceptable ranges - are able to consistently generate the targeted quality of process intermediates and active substance (i.e. appropriate purity/impurity profile for the given stage). 8/11
9 Reprocessing Reprocessing, as defined in ICH Q7, could be considered in exceptional circumstances. For biological products, these situations are usually restricted to some refiltration or re-concentration steps upon technical failure of equipment. These steps should be appropriately described and validated in the regulatory submission. Such documentation should include the demonstration that the reprocessing step(s) do(es) not impact the quality of the active substance and the description of conditions for which reprocessing could be applied (e.g. equipment failure). An essential prerequisite for the acceptance of a reprocessing step is the clearly identified root cause Hold time, storage and transportation Where hold times or storage are applied to process intermediates, the impact of the hold times and conditions on the product quality should be appropriately evaluated. The evaluation should be conducted as real-time, real-conditions studies, usually on commercial scale material. However, labscale studies could additionally be considered if appropriately justified. A selection of stability indicating assays and parameters addressing for example the biological activity, protein aggregation and degradation, ph and bioburden should be applied in order to justify a maximum hold time for each process step. Studies conducted under worst case conditions and/or abnormal conditions (e.g. higher temperature, longer time) could be used to further support the suitability of the claimed conditions. The suitability of the studies to support the claimed cumulative hold time should be discussed by the applicant. Provided the intermediate is stable and allows meaningful analyses, studies of separate steps are likely to be sufficient. Shipping and transportation of intermediates and active substance should be validated. Such study should include demonstration that the quality of the intermediate or active substance will not be altered if transported according to the defined conditions. A short summary of the study should be provided in the dossier Multifacility production During the lifecycle of biotechnological medicinal products, authorisation of additional manufacturing sites may be required to meet market demand. The process established at the new site generally requires technical adaptations of the approved process (e.g. scale up, different filters) in order to accommodate the equipment and provisions of the additional site. The adapted process should be capable of achieving comparable outputs when operating within the same input ranges. In addition to the successful demonstration of comparability of products manufactured from the different sites, it must be demonstrated that the subsequent site has reached a validated state. The relevance of previous validation studies should be discussed. Where appropriate, it may be necessary to re-demonstrate that models perform as expected. There is normally no expectation to reevaluate the complete process (e.g. clearance of impurities). Nevertheless, process verification studies should be part of the submission. Depending on the differences between the sites and the demonstration that previous validation studies are suitable representation of the new site, the ongoing process verification could reduce the amount of process verification data to be submitted. Optimisations of the production by using new processes (e.g. addition of new purification steps, replacement of one step with another (such as size-exclusion chromatography with ion exchange 9/11
10 chromatography), different conditions in buffers) is considered to constitute an alternate process and is not allowed within the same marketing authorisation. Definitions Continuous process verification An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated (ICH Q8). Control strategy A planned set of controls, derived from current product and process understanding that ensures process performance and product quality. The controls can include parameters and attributes related to active substance and finished product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control (ICH Q10). Feedback The modification or control of a process or a system based on its results and effects. Feed forward The modification or control of a process or a system using its anticipated results or effects. Feed forward and/or feedback loop Adjustments to the process based on feed forward or feedback information. High-impact model A model can be considered high-impact if prediction from the model is a significant indicator of quality of the product. Normal operating range (NOR) The NOR describes a region around the target operating conditions that contains typical operational variability and is within the claimed acceptable ranges. As such NORs themselves are not expected to be submitted in the dossier for a biological product. Ongoing process verification Documented evidence that the process remains in a state of control during commercial manufacture. Platform manufacturing The approach of developing a production strategy for a new drug starting from manufacturing processes similar to those used by the same applicant to manufacture other drugs of the same type (e.g. as in the production of monoclonal antibodies using predefined host cell, cell culture, and purification processes, for which there already exists considerable experience). Process validation The documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a medicinal product meeting its predetermined specifications and quality attributes. 10/11
11 Process evaluation Studies, performed at small and/or full scale, should provide evidence that the complete manufacturing process and each step/operating unit have been appropriately designed and are controlled to obtain a product of the intended quality. Process verification Studies which should confirm that the final manufacturing process performs effectively and is able to produce an active substance or intermediate meeting its predetermined acceptance criteria, on an appropriate number of consecutive batches produced with the commercial process and scale. References ICH Q5A (R1) Guideline on quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin (CPMP/ICH/295/95) ICH Q6B Guideline on specifications: test procedures and acceptance criteria for biotechnological /biological products (CPMP/ICH/365/96) ICH Q7 Guideline on good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00) ICH Q10 Guideline on Pharmaceutical quality system (EMA/INS/GMP/79818/2011) ICH Q11 Guideline on development and manufacture of drug substances (chemical entities and biotechnological/biological entities) (EMA/CHMP/ICH/425213/2011) 11/11
Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission
28 April 2016 EMA/CHMP/BWP/187338/2014 Committee for Medicinal Products for Human Use (CHMP) Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be
Workshop on process validation
Workshop on process validation CMC Strategy Forum Europe 2013 EBE Process validation satellite session Pragues, 06/05/2013 Kowid Ho Scope / background Process evaluation/validation of biotechnology derived
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
Workshop on process validation
Workshop on process validation General concepts on process validation Kowid Ho Scope / background Process evaluation/validation of biotechnology derived proteins used as active substance in the manufacture
Guideline on Process Validation
1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /
ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)
November 2012 EMA/CHMP/ICH/425213/2011 ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) Step 5 Transmission to CHMP May
ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) Q11
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES
Questions and answers on post approval change management protocols
30 March 2012 EMA/CHMP/CVMP/QWP/586330/2010 Committee for Medicinal Products for Human Use (CHMP) Questions and answers on post approval change management protocols Draft agreed by CHMP / CVMP Quality
ICH Topic Q 5 E Comparability of Biotechnological/Biological Products
European Medicines Agency June 2005 CPMP/ICH/5721/03 ICH Topic Q 5 E Comparability of Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS SUBJECT TO CHANGES
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) NOTE FOR GUIDANCE ON PROCESS VALIDATION
The European Agency for the Evaluation of Medicinal Products London, 1 March 2001 CPMP/QWP/848/96 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
Manufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
Questions and answers on post approval change management protocols
27 October 2010 EMA/CHMP/CVMP/QWP/586330/2010 Questions and answers on post approval change management protocols Draft Draft Agreed by QWP September 2010 Adoption by CHMP for release for consultation 23
Guideline on process validation for finished products - information and data to be provided in regulatory submissions
21 November 2016 EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1,Corr.1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on process validation
CHMP/BWP DRAFT GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use London, 28 June 2006 Doc. Ref. EMEA/CHMP/BWP/398498/2005-corr CHMP/BWP DRAFT GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL
Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use CHMP/437/04 London, 30 October 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
ICH guideline Q8, Q9 and Q10 - questions and answers volume 4
December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December
Guideline on stability testing for applications for variations to a marketing authorisation
21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER DISCUSSION IN THE HMPWG 2003-2005 RELEASE FOR CONSULTATION December 2005 DEADLINE
ICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
PRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY
PRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY Guideline Title Production and Quality Control of Medicinal Products derived by recombinant DNA Technology Legislative
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY
Guideline on similar biological medicinal products
23 October 2014 CHMP/437/04 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft agreed by Biosimilar Medicinal Products Working Party and Biologics Working Party March 2013 Adopted by CHMP
CHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use London, 24 July 2008 Doc. Ref. EMEA/CHMP/BWP/398498/2005 CHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL
Guidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing
Guidance for Industry Monoclonal Antibodies Used as Reagents in Drug Manufacturing U.S. Department of Health and Human Services Food and Drug Administration enter for Drug Evaluation and Research (DER)
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency CHMP/QWP/297/97 Rev 1 corr EMEA/CVMP/1069/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON SUMMARY
European Medicines Agency
European Medicines Agency July 1996 CPMP/ICH/139/95 ICH Topic Q 5 B Quality of Biotechnological Products: Analysis of the Expression Construct in Cell Lines Used for Production of r-dna Derived Protein
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION
Biopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
What to control? CQAs and CPPs
What to control? CQAs and CPPs Dr. Thomas Stangler On behalf of the European Generic medicines Association Development Strategy & Technology Manager Sandoz Biopharmaceuticals 1 Martin Schiestl Singapore,
Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control
ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Step 5
European Medicines Agency September 1999 CPMP/ICH/365/96 ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON SPECIFICATIONS:
Submission of comments on 'Concept paper on storage conditions during transport' (EMA/INS/GMP/638479/2010)
28 February 2011 Submission of comments on 'Concept paper on storage conditions during transport' (EMA/INS/GMP/638479/2010) Comments from: European Industrial Pharmacists Group (EIPG) Please note that
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q6B. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE
Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Inspections London, 19 May 2005 CPMP/QWP/4359/03 EMEA/CVMP/205/04 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 *
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/INF 11/2015 1 April 2015 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 * * Entry into force:
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE QUALITY OF BIOTECHNOLOGICAL PRODUCTS: ANALYSIS
Draft agreed by Pharmacokinetics Working Party January 2011. Adoption by CHMP for release for consultation 17 February 2011
17 November 2011 EMA/CHMP/600958/2010/Corr.* Committee of Medicines for Human Use (CHMP) Appendix IV of the Guideline on the Investigation on Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of
PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION
April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
European Medicines Agency Inspections London, 17 December 2003 CPMP/QWP/122/02, rev 1 corr COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON STABILITY TESTING: STABILITY TESTING OF EXISTING
Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
Reflection paper on clinical aspects related to tissue engineered products
1 2 3 19 March 2012 EMA/CAT/CPWP/573420/2009 Committee for Advanced Therapies (CAT) 4 5 6 Reflection paper on clinical aspects related to tissue engineered products Draft Draft agreed by CPWP 7 October
Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development
Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development Protein Quantification workshop, Waters: 13 th November 2012 Vincent Monchois, R&D and Pilot Services Manager,
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
ASEAN GUIDELINE ON SUBMISSION OF MANUFACTURING PROCESS VALIDATION DATA FOR DRUG REGISTRATION
ASEAN GUIDELINE ON SUBMISSION OF MANUFACTURING PROCESS VALIDATION DATA FOR DRUG REGISTRATION TABLE OF CONTENTS 1. INTRODUCTION... 2 2. SCOPE... 2 3. DATA SUBMISSION REQUIREMENTS... 2 4. CONTENT OF DEVELOPMENT
GUIDELINES ON VALIDATION APPENDIX 4 ANALYTICAL METHOD VALIDATION
June 2016 Draft document for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 GUIDELINES ON VALIDATION APPENDIX
ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5
European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND
Implementing New USP Chapters for Analytical Method Validation
Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: Ludwig_Huber@labcompliance.com Today s Agenda Handling Method Changes vs. Adjustments
Considerations for veterinary scientific advice and marketing authorisations
Considerations for veterinary scientific advice and marketing authorisations Presented by: Mary O Grady Irish Medicines Board An agency of the European Union Veterinary scientific advice Veterinary marketing
Draft Agreed by Pharmacokinetics Working Party January 2011. End of consultation (deadline for comments) 31 May 2011
1 2 3 17 February 2011 EMA/CHMP/600958/2010 Committee of Medicines for Human Use (CHMP) 4 5 6 7 8 Appendix IV of the Guideline on the Investigation on Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation
PHARMACEUTICAL DEVELOPMENT
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL DEVELOPMENT Q8(R2) Current Step
Adoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
End of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
CERTIFICATION POLICY DOCUMENT Content of the dossier for chemical purity and microbiological quality
GG/CB PUBLIC DOCUMENT (LEVEL 1) English only PA/PH/CEP (04) 1, 5R Strasbourg, August 2015 Certification of suitability to Monographs of the European Pharmacopoeia CERTIFICATION POLICY DOCUMENT Content
The European Pharmacopoeia and certificates of suitability (CEP)
The European Pharmacopoeia and certificates of suitability (CEP) Your Logo Andrew McMath Ph.D. European Directorate for the Quality of Medicines (EDQM) Presented by: Andrew McMath Scientific Officer, EDQM
Work instructions. 1. Changes since last revision. 2. Records. 3. Instructions EXPLANATORY NOTES
Work instructions Title: Calculation of fees for GMP and product related inspections Applies to: P-CI-MQC staff Status: PUBLIC Document no.: WIN/INSP/2043 Lead Author Approver Effective Date: 13-APR-12
PHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
Quality and Safety Evaluation of Gene Therapy Products in Japan
Quality and Safety Evaluation of Gene Therapy Products in Japan Review Mechanism for Gene Therapy in Japan The review mechanism for gene therapy in Japan was partially amended to simplify the necessary
Expectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
IMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
Synopsis: FDA Process Validation Guidance
Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.
ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients questions and answers
23 July 2015 EMA/CHMP/ICH/468930/2015 Committee of Human Medicinal Products ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients questions and answers Step 5 Transmission
Luca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
Guidance for Industry
Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
Workshop A Design Space (DS)
Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information
Guideline for Industry
Guideline for Industry Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products July 1996 ICH Q5C Table of Contents I. INTRODUCTION (1)... 1 II. SCOPE OF THE ANNEX
Biotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
Process Validation of Macugen API:
Process Validation of Macugen API: An Exercise in Submission Preparation and Inspection Readiness Patrick Giljum Head of Operations BioTechLogic, Inc. Today s Discussion Process Validation of Macugen API:
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/31329/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL
VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
Guidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.
15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2
A Parker domnick hunter White Paper. Controlling bioburden within biopharmaceutical manufacturing processes
A Parker domnick hunter White Paper Controlling bioburden within biopharmaceutical manufacturing processes Table of contents Introduction...3 Minimizing bioburden in biopharmaceutical manufacturing processes...4
GUIDELINE ON REQUIREMENTS FOR REVISION/RENEWAL OF CERTIFICATES OF SUITABILITY TO THE EUROPEAN PHARMACOPOEIA MONOGRAPHS
PPR/CB PUBLIC DOCUMENT (LEVEL 1) English only/anglais seulement PA/PH/CEP (04) 2, 6R Strasbourg, July 2014 Certification of suitability to the Monographs of the European Pharmacopoeia GUIDELINE ON REQUIREMENTS
Control Strategy as the Keystone of the Product Lifecycle, from Product/ Process Understanding to Continuous Process Verication and Improvement
Online Exclusive from PHARMACEUTICAL ENGINEERING The Ofcial Magazine of ISPE January/February 2012, Vol. 32 No. 1 www.pharmaceuticalengineering.org Copyright ISPE 2012 This article presents the general
Tutorial on Reference Materials / Standards
Tutorial on Reference Materials / Standards Co-chaired by: Dieter Schmalzing, Barry Cherney, Nancy Kirschbaum, Juhong Liu, Markus Blümel January 29, 2013 WCBP 2013, Washington, DC Disclaimer This tutorial
Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers (R4)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & (R4) Current version dated
Draft agreed by JEG 3Rs June Adopted by CVMP for release for consultation 14 July 2016
1 2 3 4 21 July 2016 EMA/CHMP/CVMP/JEG-3Rs/677407/2015 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 7 8 9 Review and update of EMA
Process Validation: Practical Aspects of the New FDA Guidance
Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
Valentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
Analytical Procedures and Methods Validation for Drugs and Biologics
Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Importing pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
Guideline on the use of porcine trypsin used in the manufacture of human biological medicinal products
20 February 2014 EMA/CHMP/BWP/814397/2011 Committee for Medicinal Products for Human use (CHMP) Guideline on the use of porcine trypsin used in the manufacture of human biological Draft Agreed by Biologicals
2008 USPC Official 12/1/07-4/30/08 General Chapters: <1225> VALIDATION OF C...Page 1 of 10
2008 USPC Official 12/1/07-4/30/08 General Chapters: VALIDATION OF C...Page 1 of 10 1225 VALIDATION OF COMPENDIAL PROCEDURES Test procedures for assessment of the quality levels of pharmaceutical
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current
Assay Qualification Template for Host Cell Protein ELISA
Assay Qualification Template for Host Cell Protein ELISA Introduction: With ever increasing importance being placed on host cell protein (HCP) removal during the purification process, it is critical to
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
Quality by Design Trevor Schoerie
Quality by Design Trevor Schoerie Guidelines Please contribute and ask questions Please relax and enjoy yourself Phone on silent / mute? Native presentation can be emailed. Slide 2 Agenda The what, who,
ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/380/95 ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal
Application Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
Quality by Design Application and Perspectives for biologicals. K. Ho, CHMP Biologics Working Party
Quality by Design Application and Perspectives for biologicals K. Ho, CHMP Biologics Working Party Pharmaceutical development (Q8) Aim: To design a quality product and a manufacturing process to consistently
Analytical Method Validation
Analytical Method Validation A. Es-haghi Ph.D. Dept. of Physico chemistry vaccine and serum research institute a.eshaghi@rvsri.ir http://www.rvsri.ir/ Introduction Test procedures for assessment of the
Regulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research